# Complex Regional Pain Syndrome: Diagnosis and Multidisciplinary Management

## Overview
Chronic pain condition characterized by pain disproportionate to inciting event, with sensory, vasomotor, sudomotor/edema, and motor/trophic changes. Previously termed reflex sympathetic dystrophy (CRPS type I) and causalgia (CRPS type II). CRPS type I: no identifiable nerve injury; CRPS type II: associated with documented nerve injury. Incidence: 5-26 per 100,000 person-years.

Female:male ratio approximately 3-4:1. Most common age: 40-60 years. Upper extremity affected more than lower extremity (60% vs 40%). Common precipitants: fractures (most common), surgery, soft tissue injury, immobilization.

## Budapest Diagnostic Criteria (2003, validated 2010)
Must meet ALL four requirements: 
### 1. Continuing pain disproportionate to inciting event

### 2. At least ONE sign in TWO or more of these categories:
**Sensory**: hyperalgesia and/or allodynia. **Vasomotor**: temperature asymmetry, skin color changes/asymmetry. **Sudomotor/edema**: edema, sweating changes/asymmetry. **Motor/trophic**: decreased ROM, motor dysfunction (weakness, tremor, dystonia), trophic changes (hair, nail, skin).

### 3. At least ONE symptom (patient-reported) in THREE or more categories:
**Sensory**: hyperesthesia, hyperalgesia. **Vasomotor**: temperature asymmetry, skin color changes. **Sudomotor/edema**: edema, sweating changes. **Motor/trophic**: decreased ROM, motor dysfunction, trophic changes.

### 4. No other diagnosis better explains signs and symptoms

<image>Budapest diagnostic criteria for CRPS with clinical photographs showing vasomotor, sudomotor, and trophic changes</image>

## Pathophysiology
Multimechanistic - no single unifying theory.

### Peripheral Mechanisms
Neurogenic inflammation: release of substance P, CGRP from sensitized nociceptors. Peripheral sensitization with upregulated sodium channels. Small fiber neuropathy (even in CRPS type I). Oxidative stress and local tissue hypoxia.

### Central Mechanisms
Central sensitization: dorsal horn wind-up, NMDA receptor activation. Cortical reorganization: shrinkage of affected hand representation in somatosensory cortex. Disinhibition of pain-processing pathways. Body perception disturbance (affected limb feels foreign, larger).

### Autonomic Dysfunction
Early (warm phase): inhibition of sympathetic vasoconstriction → warmth, redness, edema. Late (cold phase): sympathetic hyperactivity → cold, pale/cyanotic, dry skin. Sympatho-afferent coupling: norepinephrine activates nociceptors.

### Inflammatory/Immune
Elevated pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). Autoantibodies against autonomic receptors identified in some patients. Mast cell activation and neurogenic inflammation.

### Psychological Factors
NOT a psychogenic condition. Psychological distress is a consequence, not a cause. Anxiety, depression, catastrophizing may modulate pain processing. Prior life stress may be a vulnerability factor.

## Clinical Stages (Classic Description)
Note: not all patients follow this staging; it has limited clinical utility.

### Stage 1 (Acute/Warm) - 0-3 months
Burning pain, hyperalgesia, allodynia. Warm, red, edematous limb. Increased sweating. Increased hair and nail growth.

### Stage 2 (Dystrophic) - 3-6 months
Persistent pain, spreading. Cool, cyanotic skin. Decreased hair growth, brittle nails. Early joint stiffness. Osteopenia on X-ray.

### Stage 3 (Atrophic) - >6 months
Pain may decrease or persist. Pale, cool, atrophic skin. Joint contractures. Significant osteoporosis. Muscle wasting. Often irreversible changes.

| Stage | Timeframe | Temperature | Skin Appearance | Edema | Trophic Changes | Prognosis |
|-------|-----------|-------------|-----------------|-------|-----------------|-----------|
| 1 (Acute/Warm) | 0-3 months | Warm | Red, flushed | Present | Increased hair/nail growth | Best if treated early |
| 2 (Dystrophic) | 3-6 months | Cool | Cyanotic | Variable | Decreased hair, brittle nails | Moderate |
| 3 (Atrophic) | >6 months | Cool | Pale, atrophic | Minimal | Contractures, osteoporosis, wasting | Often irreversible |

## Diagnostic Workup
CRPS is a clinical diagnosis - no single confirmatory test. Supportive investigations: **Triple-phase bone scan**: increased uptake in affected region (sensitivity 50-70%, specificity 80-90%), most useful in early CRPS. **Plain radiographs**: patchy osteoporosis (Sudeck atrophy), occurs later.

**Temperature asymmetry**: > 1°C difference between affected and unaffected side (quantitative thermography). **Quantitative sudomotor axon reflex test (QSART)**: asymmetric sweating. **MRI**: bone marrow edema, soft tissue edema (nonspecific). **Electrodiagnostic studies**: normal in CRPS type I; nerve injury findings in CRPS type II. Exclude: infection, DVT, fracture, compartment syndrome, vascular insufficiency.

<image>Diagnostic workup for CRPS showing triple-phase bone scan, thermography, and radiographic findings</image>

## Treatment Approach

### Principles
Early, aggressive, multidisciplinary treatment. Functional restoration is the primary goal. Graded exposure to movement and sensation. Address fear-avoidance and pain catastrophizing. Treatment becomes less effective with chronicity.

### Rehabilitation/Physical Therapy (Foundation of Treatment)

#### Graded Motor Imagery (GMI)
Three-stage progressive program: 1. **Laterality recognition**: identifying left vs. right limb images (activates premotor cortex without pain). 2. **Motor imagery**: imagining movements of the affected limb (further cortical activation). 3. **Mirror therapy**: watching unaffected limb in mirror while performing bilateral movements (visual-motor cortical normalization).

Evidence: Level 1 for pain reduction and function improvement. Requires daily practice (10-15 minutes, multiple times daily).

#### Desensitization
Progressive exposure to increasingly intense stimuli. Graded textures, temperatures, pressures applied to affected area. Addresses allodynia and hyperesthesia. Must be done gradually to avoid flare.

#### Active Exercise
Pain-free or pain-limited active ROM. Progressive loading and strengthening. Aquatic therapy may be better tolerated. Avoid immobilization (worsens CRPS). Stress loading program: scrubbing and carrying activities.

#### Edema Management
Elevation, compression garments, retrograde massage. Manual lymphatic drainage. Contrast baths (controversial - may worsen vasomotor instability).

### Pharmacologic Management

#### First-Line
**NSAIDs**: early anti-inflammatory effect. **Corticosteroids**: short course (prednisone 30-40 mg/day taper over 2-4 weeks) - most effective in early, inflammatory CRPS. **Gabapentinoids**: pregabalin 150-600 mg/day or gabapentin 900-3600 mg/day. **Tricyclic antidepressants**: nortriptyline or amitriptyline 25-150 mg.

#### Second-Line
**Bisphosphonates**: alendronate, neridronate, pamidronate IV. Address bone resorption component. Some evidence for pain reduction beyond bone effects. Neridronate has strongest evidence.

**SNRIs**: duloxetine 60-120 mg. **Topical agents**: lidocaine 5% patches, capsaicin 8% patch, DMSO 50% cream (not available in US). **Calcitonin**: nasal spray, limited evidence.

#### Third-Line
**Ketamine**: IV infusions (low-dose subanesthetic). NMDA receptor antagonist addressing central sensitization. Growing evidence but variable protocols. Requires monitored setting.

**Opioids**: generally avoided; limited efficacy, risk of dependence. **Low-dose naltrexone**: emerging evidence, anti-neuroinflammatory mechanism. **Immunoglobulin (IVIG)**: for autoimmune/inflammatory subtype, limited evidence.

### Interventional Procedures

#### Sympathetic Nerve Blocks
Stellate ganglion block (upper extremity) or lumbar sympathetic block (lower extremity). Diagnostic: confirms sympathetically maintained pain (SMP) component. Therapeutic: temporary relief; series of blocks with concurrent therapy. Not all CRPS has SMP component (sympathetically independent pain also exists).

#### Spinal Cord Stimulation
Dorsal column stimulation for refractory CRPS. KEMSTIM and ACCURATE trials: Level 1 evidence for CRPS pain reduction. Consider after failure of conservative management (3-6 months). Trial stimulation before permanent implant. May improve function and quality of life.

#### Intrathecal Drug Delivery
Baclofen for CRPS-related dystonia. Opioid/ziconotide for refractory pain. Reserved for severe, refractory cases.

<image>Treatment algorithm for CRPS showing stepwise approach from rehabilitation through interventional procedures</image>

## Prognosis
Early treatment (within 3-6 months) associated with better outcomes. 50-70% achieve significant improvement with multimodal treatment. 15-25% develop chronic, refractory CRPS. Spontaneous remission can occur. Recurrence rate: 10-30%. Spread to other limbs can occur (contralateral, ipsilateral).

## Clinical Pearls
CRPS is a clinical diagnosis using Budapest criteria - no lab test or imaging study can confirm or exclude it. Early aggressive rehabilitation with graded motor imagery and desensitization is the foundation of treatment, not pharmacology. Short-course corticosteroids (prednisone taper) are most effective when CRPS is caught early in the inflammatory phase. Immobilization and protective guarding worsen CRPS - educate patients that movement is therapeutic despite being painful. If a patient with CRPS has dystonia, consider intrathecal baclofen trial - this is often a neglected treatment option.

## References
- Harden RN, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for complex regional pain syndrome. Pain. 2010;150(2):268-274.
- Birklein F, et al. Complex regional pain syndrome: an update. Pain Rep. 2021;6(1):e929.
- Shim H, et al. Complex regional pain syndrome: a narrative review for the practising clinician. Br J Anaesth. 2019;123(2):e424-e433.
- Smart KM, et al. Mechanisms-based classifications of musculoskeletal pain. Clin J Pain. 2011;27(7):655-663.
- O'Connell NE, et al. Interventions for treating pain and disability in adults with complex regional pain syndrome. Cochrane Database Syst Rev. 2013;(4):CD009416.